Chimeric antigen receptor T (CAR-T) cell therapy is actively under study for the treatment of relapsed and refractory multiple<unk> . This form of cell-based therapy employs one's own T lymphocytes, which are engineered to be tumor-specific. The antigen of interest for multiple<unk>  CAR-T therapy is B cell maturation antigen (BCMA). Other<unk>  therapies include lymphoma-like polychemotherapy regimen and Bruton's tyrosine kinase inhibitor CC-292.
Multiple myeloma future or investigational therapies
Multiple myeloma medical therapy
Monoclonal gammopathy of undetermined significance secondary prevention
Myeloproliferative neoplasm future or investigational therapies
Primary amyloidosis medical therapy
POEMS syndrome medical therapy
Secondary amyloidosis medical therapy
Familial amyloidosis medical therapy